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1 Introduction
During pregnancy physiological alterations occur
in the coagulation and fibrinolytic systems. Bie-
zinski et al. reported in 1958 [4] that plasma fi-
brinolytic activity, measured in euglogulin precip-
itates, is decreased in pregnant women. These al-
terations may play an important role in placental
haemostasis.
Several studies have shown a rapid rise of the
plasma fibrinolytic activity shortly after childbirth
and separation of the placenta [13,14]. During the
process of placental separation a blood flow of
500-800 mls/min to the placental bed has to be
staunched. The activation of the coagulation in
the placental bed has to be localized to the uterus
to prevent intravascular clotting. This is achieved
by the inhibitors of coagulation and the fibrino-
lytic system.
In the newborn infant an increased fibrinolytic
activity has been reported [3].
2 Patients and methods
2.1 Subjects
Twenty-six healthy pregnant women (age range
16 — 35 years) at term with no evidence of pre-
eclamsia, eclamsia or overt thromboembolic dis-
ease were studied. None of these women had a
history of thromboembolic disease.
Of the twenty-six subjects thirteen pregnant
women were primigravidae. Twenty-two patients
were studied during normal childbirth, four pa-
tients during elective caesarean section. Full and
informed consent was given by each patient for
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specimens of blood to be taken with a minimum
of venous occlusion from an ante-cubital vein in
the second and third stage of labour, and at 48
and 72 hours after delivery. Blood was also taken
from the umbilical vein on the maternal side im-
mediately following childbirth, after clamping the
cord, and befor delivery of the placenta.
2.2 Fibrinolytic assays
5 ml of blood was taken directly into plastic sy-
ringes containing sodium citrate as an anticoagu-
lant with a minimum of venous occlusion. For
determination of functional t-PA activity 2 ml of
blood was immediately mixed with 1 ml of 10%
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acetate buffer, centrifuged and further acidified
with 20% acetic acid to assure a pH of 4.0—4.1.
All samples were snap-frozen in liquid nitrogen,
stored at — 80 °C and assayed within four weeks.
t-PA antigen was determined using a sensitive en-
zyme linked immunosorbent assay (ELISA) utiliz-
ing the double antibody principle [17]. This assay
measures not only free t-PA but also inhibitor-
ecomplexed t-PA. The t-PA functional activity was
measured using an enzymatic assay involving a
three-stage reaction: t-PA is stimulated by soluble
des-AA fibrin, glu-plasminogen is converted to
plasmin by catalysation of stimulated t-PÄ, the
substrate D-But-CHT-Lys-pNA is then hydro-
lysed to free pNA by plasmin [18]. In this assay
all free t-PA inhibitors present were destroyed by
acidification of the sample. Thus the total t-PA
activity could be measured.
For determination of the t-PA inhibitor an indirect
enzymatic assay was performed in two stages [5].
In stage 1 t-PA reacts with the free PAI present
in the specimen. In stage 2 the residual t-PA ac-
tivity is measured by using the t-PA activity assay.
The PAI content is then determined as the differ-
ence between the amount of t-PA added and the
amount of t-PA found.
2.3 Statistical analysis
Data were analysed using the Mann-Whitney-Wil-
coxon test and the paired t-test. Time-series cross-
correlation analysis was applied to the data. Mean




t-PA antigen levels in maternal plasma in the sec-
ond stage of labour were found to be three fold
higher than in the plasma of non-pregnant women
(8.66 ng/ml, S. D. 4.75 ng/ml). During late labour
from second to third stage t-PA antigen increased
significantly (p < 0.05, Mann-Whitney-Wilcoxon)
to 11.96 ng/ml (S.D. 4.61 ng/ml). A marked de-
crease of t-PA levels (p < 0.001) was observed
between the third stage of labour and 48 and 72
hours after delivery (figure 1).
The mean t-PA antigen values in the cord blood
of the newborn (9.18 ng/ml, S. D. 6.94 ng/ml) were
found to be in the same range as the mothers'
levels in the second stage of labour. A significant
difference (p < 0.01) to maternal t-PA antigen lev-
els in the early puerperium was observed (figure 2).
No significant differences in the t-PA antigen levels
were found when comparing the primiparous pa-
tients with the multiparous patients or the patients
who delivered by caesarean section with the pa-
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Figure 1. Plasmat-PA antigen levels during and after
normal childbirth. The results are expressed as the mean




Figure 2. Comparison of t-PA antigen levels in cord
blood and materaal blood before delivery of the pla-
centa. The results are expressed as the mean ± the
standard error of the mean.
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Figure 3. Plasmat-PA activity levels during and after
normal childbirth. The results are expressed as the mean




Figure 4. Comparison of t-PA activity levels in cord
blood and maternal blood before delivery of the pla-
centa. The results are expressed as the man ± the stan-
dard error of the mean.
3.2 t-PA Activity
Figure 3 shows the total t-PA activity during late
labour and early puerperium. The trend obtained
was similar to that found when measuring the t-
PA antigen levels. The changes were statistically
significant when comparing the second (0.278 IU/
ml, S. D. 0.093 lU/ml) with the third stage (0.365
lU/ml, S.D. 0.124 lU/ml) of labour (p < 0.05,
Mann-Whitney-Wilcoxon) and the third stage of
labour with 48 hours (0.258 lU/ml, S.D. 0.127
lU/ml) and 72 hours (0.263 lU/ml, S. D. 0.100 IU/
ml) after delivery (p < 0.05). The t-PA activity
showed an increase of more than 30% between
second and third stage of labour. At 48 and 72
hours after childbirth the values had returned al-
most to those of the second stage of labour.
The t-PA activity found in the umbilical cord
plasma was high (1.190 lU/ml, S. D. 1.108 lU/ml)
when compared to the maternal plasma during
both stages of labour (p < 0.003). The difference
was also highly significant when comparing the
cord values with those of the first three days post
partum (p < 0.001). The relation between the cord
t-PA activity and the plasma t-PA activity in the
third stage of labour is shown in figure 4.
The t-PA activity levels in the newborn cord blood
after ceasarean section were found to be signifi-
cantly lower than in the cord blood after sponta-
neous uncomplicated delivery (p < 0.03). No sig-
nificant difference was found between primiparae
and multiparae.
3.3 t-PA Inhibitor
The total inhibitory activity of PAI in plasma was
found to be five to six times higher in the 2nd
stage of labour (22.84 lU/ml, S. D. 6.21 IU/ml)
than in normal human plasma and showed a slight
but nonsignificant decrease in the third stage of
labour (22.43 IU/ml, S.D. 5.50 IU/ml). At 48
hours after delivery (9.71 IU/ml, S.D. 4.31 IU/
ml) a decline of more than 50% (p < 0.001) in
PAI activity was observed. 72 hours after delivery
(9.61 IU/ml, S.D. 4.74 IU/ml) the values still
remained at this low level. The difference was not
significant when compared with the values at 48
hours post delivery (figure 5).
PAI plasma levels found in the cord blood were
approximately one third of the maternal plasma
levels (7.06 IU/ml, S. D. 6.08 IU/ml) during the
third stage of labour (p < 0.001) (figure 6). Also
the 48 hours PAI plasma levels of the mother were
significantly higher (p < 0.05) than the cord PAI
levels.
No difference was found between primiparae and
multiparae or patients with vaginal delivery and
patients who delivered by caesarean section.
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Figure 5. Plasma PA inhibitor activity levels during and
after normal childbirth. The results are expressed as the










Figure 6. Comparison of PA inhibitor activity levels in
cord blood and maternal blood before delivery of the
placenta. The results are expressed as the mean + the
standard error of the mean.
3.4 Time series cross-correlation
When t-PA antigen values (figure 1) were cross-
correlated with t-PA inhibitor values (figure 5) a
cross-correlation coefficient of 0.94 was obtained.
A cross-correlation coefficient value of 0.89 was
obtained when the t-PA antigen (figure 1) time
series was cross-correlated with the t-PA activity
(figure 3) time series.
Table. Significance values of t-PA antigen and PA inhibitor activity in newborn cord plasma and in maternal plasma







































Previous studies in coagulation and flbrinolysis
during uncomplicated pregnancy and normal
childbirth have indicated profound changes in the
haemostatic system towards hypercoagulability
[11, 9]. Both blood coabulation and flbrinolytic
parameters return to normal within the first three
weeks of puerperium [7]. The overall flbrinolytic
activity of newborn cord blood has been reported
to be on a higher level than that of the mother at
term [8, 10].
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Our data confirm that marked changes in the1
levels of t-PA antigen, activity and inhibitor take
place during delivery and in the early puerperium.
t-PA antigen levels have been reported to be in-
creased in the second half of pregnancy [13]. Pre-
vious studies [13, 14] have revealed a further rise
in t-PA antigen shortly after delivery of the pla-
centa. Our results show that the t-PA antigen levels
in maternal plasma increase immediately following
childbirth, before delivery of the placenta. This
rise may be explained by a t-PA release from the
vessel walls in the placental bed during the process
of placental separation.
Oxytocin and stress hormones such as epinephrine
have been shown to be capable of freeing plas-
minogen activators [6]. Strong contractions of
uterine myometrium during labour and in partic-
ular in the late second stage can cause a t-PA
release from the vascular endothelium.
Previous studies of plasma t-PA activity before
and after childbirth revealed conflicting results
more likely due to the different assays used [13,
14]. We found a significant increase of t-PA activ-
ity between the second and the third stage of
labour; to our knowledge none of the previous
studies had investigated this period immediately
after delivery of the baby.
The increase corresponds to the trend of the t-PA
antigen levels found in maternal plasma. Mack-
innon et al. [14] showed that the t-PA antigen
decreases to near normal values three to five days
after delivery. Our findings are similar, at 48 hours
after childbirth a steep decrease to near normal
values had already occurred. The values at 72
hours remained in the same range. The t-PA ac-
tivity pattern in maternal plasma follows the same
trend as the t-PA antigen pattern although the
significant changes are less striking.
During the last few years several studies on t-PA
inhibitors have reported the existence of at least
three distinct plasminogen activator inhibitors:
PAI1, the so called fast acting inhibitor, purified
from endothelial cells [16], PAI 2, the placental
type inhibitor found in trophoblastic endothelium
[1, 2] and protease nexin [19]. To determine the
overall fibrinolytic status of the mother the present
study investigated the relation between the total
inhibitory activity andthe activator activity with-
out discriminating between the different types of
plasminogen activator inhibitors. In recent studies
high levels of PAI activity were found in the second
stage of labour, the reported PAI activity values
measured shortly after delivery of the placenta
showed a significant decline [13, 14]. Our data
confirm these second täte PAI activity findings.
However we found that the PAI activity plasma
levels in the third stage before placental delivery
still remained at this high level. At 48 hours after
delivery a striking decrease in the overall PAI
activity was fond while the measurement at 72
hours showed no further change. These results are
possibly due to the separation of the placenta
which is known to be a rich source of fibrinolytic
inhibitors [12]. With placental separation an im-
portant site of inhibitor production in pregnancy
ceases resulting in the significant decrease in in-
hibitory activity found in maternal plasma after
placental separation.
Previous studies [15] have compared the fibrino-
lytic system in the newborn cord blood with that
in the mothers' plasma at term and have found
profound differences between both groups. In the
present study blood was taken simultaneously
from the cord and the mother before placental
delivery. Thus the changes in the fibrinolytic ac-
tivity could be investigated just as the placenta
was separating. We found higher maternal levels
of t-PA antigen in the third stage of labour than
in the cord while the t-PA activity levels were lower
in the mother when compared with the cord blood.
This can be explained by the high concentration
of PAI activity present in the mothers' blood at
the third stage of labour. The PAI activity in the
cord was found to be very low so the t-PA antigen
will bind to the inhibitor in a reduced quantity.
Therefore high t-PA activity levels were found in
the infant cord blood. This high level of fibrino-
lytic activity will serve as a pretective mechanism
to prevent fibrin formation in the baby during and
after delivery [10]. The total inhibitory activity of
PAI was low in the cord before separation of the
placenta suggesting that the endothelial cells in
the umbilical cord are not involved in PAI pro-
duction. PAI seems to be selectively released into
the maternal circulation. The absence of fibrino-
lytic activity found around cytotrophoblastic cells
was considered to be due to a high level of inhib-
itor in these cells [20]. To clarify the origin of
present inhibitors it would be interesting to inves-
tigate the type of PAI found in the cord and in
cytotrophoblasts by immunological means.
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Abstract
During normal childbirth profound changes in the fi-
brinolytic system take place. Tissue plasminogen acti-
vator (t-PA), the antigen and its biological activity and.
the activity of plasminogen activator inhibitor (PAI)
were measured in twenty-two healthy women during and
shortly after spontaneous delivery (2nd stage and 3rd
stage of labour, 48 and 72 hours post partum). Signifi-
cant increases of plasma t-PA antigen and activity oc-
curred during childbirth and before delivery of the pla-
centa, while the inhibitor remained unchanged. After
delivery the PA inhibitor and t-PA antigen showed a
steep decline. The activity of t-PA remained largely un-
changed during labour and after delivery.
Keywords: Fibrinolysis, pregnancy, puerperium, tissue plasminogen activator, tissue plasminogen activator inhib-
itor.
The comparison between the activity levels of PAI in:
infant cord blood and in maternal peripheral blood,·1
taken simultaneously during the process of placentaK
separation, showed significantly higher PAI activity in
the mother. In contrast the levels of t-PA activity were
found to be significantly higher in cord blood.
Our results demonstrate that during the process of child-
birth and separation of the placenta distinct alterations
in the fibrinolytic system occur most likely due to pla-
cental effects.
Zusammenfassung
Inhibitoren und Aktivatoren der Fibrinolyse im mütterli-
chen Blut und im Nabelschnurblut während und nach der
Geburt
Während der normalen Entbindung finden umfassende
Veränderungen im fibrinolytischen System statt. Bei 22
gesunden Frauen wurden während und kurz nach einer
Spontangeburt (2. und 3. Phase der Wehentätigkeit, 48
und 72 h post partum) der zellgebundene Plasminogen-
Aktivator (t-PA), einmal als Antigen selbst und zum
anderen seine biologische Aktivität, sowie die Aktivität
des Inhibitors vom Plasminogen-Aktivator (PAI) ge-
messen. Während der Entbindung und vor der Geburt
der Plazenta kommt es zu einem signifikanten Anstieg
des t-PA-Antigen und seiner Aktivität im Plasma, wäh-
rend der Inhibitor unverändert bleibt. Nach der Entbin-
dung fallen der PAI und das t-PA-Antigen steil ab. Die
Aktivität des t-PA bleibt während und nach der Geburt
weitgehend konstant.
Der Vergleich zwischen den PAI-Aktivitätsspiegeln im
Nabelschnurblut und im maternalen peripheren Blut (die
Proben wurden simultan während der Abnabelung ent-
nommen), zeigte eine deutlich höhere PAI-Aktivität bei
der Mutter. Im Gegensatz dazu war die t-PA-Aktivität
im Nabelschnurblut signifikant höher.
Unsere Ergebnisse zeigen, daß während der Geburt und
nach Ablösung der Plazenta deutliche Veränderungen im
fibrinolytischen System stattfinden, die am ehesten von
der Plazenta ausgehen.
Schlüsselwörter: Fibrinolyse, Schwangerschaft, Wochenbett, zellgebundener Plasminogen-Aktivator und sein In-
hibitor.
Resume
Inhibiteurs et activateurs de la fibrinolyse pendant et apres
la naissance dans le sang maternel et au sang du cordon
Des modifications importantes du Systeme fibrinolytique
surviennent au cours de l'accouchement normal. Chez
22 femmes en bonne sante on a dose pendant et peu
pares la delivrance naturelle (2eme et 3eme parties du
travail, 48 et 72 heures apres) l'activateur du plasmino-
gene tissulaire (t-PA), l'antigene et son activite biolo-
gique ainsi que activite de l'inhibiteur de l'activateur
du plasminogene (PAI). Pendant la naissance et avant
la delivrance, il existe une augmentation significative de
Fantigene t. PA plasmatique et de son activite, alors que
l'inhibiteur demeure inchange. Apres la delivrance, il
existe une diminution de l'inhibiteur PA et de l'antigene
t. PA. L'activite du t. PA ne se modifie pas au cours tu
travail, et apres la delivrance.
La comparaison entre les taux d'activite du PAI au sang
du cordon et dans le sang peripherique maternel, re-
cueillis simultanement au cours du decollement placen-
taire montre une activite PAI significativement plus ele-
vee chez la mere. A l'inverse les taux d'activite t. PA sojt
significativement plus eleves au snag du cordon.
Nos resultats demontrent qu'au cours de la naussance
et du decollement placentaire surviennent des pertur-
bations du Systeme fibrinolytique secondaires tres vrais-
semblablement a des effets placentaires.
Mots-cles: Activateur tissulaire du plasminogene, fibrinolyse, grossesse, inhibiteur de l'activateur tissulaire du
plasminogene, post-partum.
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